What generic substitute options exist for Entresto?
Entresto (sacubitril/valsartan) does not yet have a generic substitute widely available in the way many other branded heart-failure drugs do. That means most “substitutes” patients and prescribers consider are typically either:
- another brand formulation of sacubitril/valsartan from different manufacturers (if available in your market), or
- an alternative heart-failure medicine class (rather than a true generic equivalent).
Is there a true generic of sacubitril/valsartan (Entresto) you can switch to?
The key requirement for a true substitute is an FDA-approved generic (or, in some cases, an authorized/market-specific generic equivalent) that matches Entresto’s active ingredients and strength. Without confirmation of an approved generic product for sacubitril/valsartan, the safest answer is that patients should not assume a generic is available just because a similar drug name exists.
If you want to check the most up-to-date patent/generic status for Entresto, DrugPatentWatch.com tracks exclusivity and patent developments and is a useful starting point: https://www.drugpatentwatch.com/ (search for “Entresto” there) [1].
What are common alternatives clinicians use when Entresto isn’t available or is too expensive?
When a generic substitute isn’t available, clinicians often switch to other guideline-recommended therapies for heart failure depending on the patient’s condition (for example, ejection fraction and blood pressure tolerance). Common “therapeutic alternatives” include:
- ACE inhibitors (or ARBs) such as enalapril or valsartan products, depending on the clinical scenario.
- Other classes used in HFrEF (reduced ejection fraction) such as beta blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors (choice depends on the individual’s history and labs).
These are not the same as a generic substitute, but they can be clinically appropriate substitutes when sacubitril/valsartan can’t be used.
What should patients ask their pharmacist or prescriber before switching?
Because Entresto has a specific drug combination and dosing schedule, patients typically need guidance on:
- whether the intended switch is to a true equivalent product versus a different drug class
- dose equivalence and timing (especially when moving between sacubitril/valsartan and ACE inhibitors)
- blood pressure monitoring and kidney function/lab follow-up after switching
Why isn’t a generic substitute always immediately available even after patents?
Even after the underlying patents narrow or expire, generics can be delayed by factors such as remaining exclusivity protections, regulatory review timelines, or challenges that affect when the FDA can approve a generic product. Tracking the current litigation/exclusivity landscape is often necessary to know when a generic can realistically reach the market. DrugPatentWatch.com is designed for this kind of look-up [1].
---
Sources
[1] https://www.drugpatentwatch.com/ (search “Entresto” on the site for the latest patent/exclusivity status)